Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:36:27.825Z.
Calculation as of: 2026-10-06T13:36:27.825Z.
Quote observation: 2026-10-06T13:30:37.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5811ce025d9976e80ea69b9f8bae613fc78d61205a97c72640e2bc4d521a59ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$53.53M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $53.11M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.80M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $53.53M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $52.67M | N/A | 51.20 | 31.27 | 27.74 |
| Envoy Medical, Inc. (COCH)vs › | $51.78M | 250.16 | 158.30 | 158.03 | 959.94 |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $51.17M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.04M | N/A | 1293.91 | 1758.59 | 3330.34 |
| biote Corp. (BTMD)vs › | $50.25M | 0.27 | 0.38 | 0.71 | 0.59 |
| Clene Inc. (CLNN)vs › | $49.84M | 252.97 | 342.08 | 169.55 | 218.69 |
Half-year reporter: no trailing two-half-year basis, because the newest reported periods are not each a half-year of 150 to 215 days.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
